Cart
sales@molnova.com
Labuxtinib
CAS No. 1426449-01-5
Labuxtinib( —— )
Catalog No. M37250 CAS No. 1426449-01-5
Labutinib is a selective inhibitor of the c-kit tyrosine kinase .
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 373 | In Stock |
|
| 5MG | 337 | In Stock |
|
| 10MG | 541 | In Stock |
|
| 25MG | 1074 | In Stock |
|
| 50MG | 1516 | In Stock |
|
| 100MG | 2037 | In Stock |
|
| 200MG | 2744 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLabuxtinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionLabutinib is a selective inhibitor of the c-kit tyrosine kinase .
-
DescriptionLabuxtinib is c-kit tyrosine kinase inhibitor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR | c-Kit
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1426449-01-5
-
Formula Weight377.37
-
Molecular FormulaC20H16FN5O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (331.24 mM; Ultrasonic )
-
SMILESC(NC1=CC(=CC=C1C)C=2N=C(ON2)[C@@H]3[C@@H](F)C3)(=O)C=4N5C(=NC4)C=CC=C5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yeh Vince, et al. Imidazopyridine compounds and compositions as c-kit kinase inhibitors and their preparation. World Intellectual Property Organization, WO2013033070 A1. 2013-03-07.
molnova catalog
related products
-
HKI-357
HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 (IC50s: 34 nM and 33 nM). HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.
-
AZD8931 diFuMaric ac...
AZD8931 is a reversible and ATP competitive inhibitor of EGFR, ErbB2 and ErbB3 (IC50 of 4 nM, 3 nM and 4 nM, respectively).AZD8931 significantly suppressed cell growth of IBC cells and induced apoptosis of human IBC cells in vitro.AZD8931 monotherapy inhibited xenograft growth.
-
Lumretuzumab
Lumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity for the study of advanced HER3-positive solid tumors and breast cancer.
